The future of multiple sclerosis treatments.
There are not many conditions in which the last few decades have brought such a major change in the landscape of treatments as is the case of multiple sclerosis (MS). A number of disease modifying treatments (DMTs) are presently available for the treatment of the inflammatory phase of this disabling disease; however, the need for treating neurodegeneration and halting the progression of disability is still unmet. Areas covered: In this paper we review the available information on existing and emerging DMTs and we discuss their place within the context of different treatment strategies in MS, Expert commentary: The future of MS treatments should include the development of new treatment strategies tackling disease progression, together with a better understanding of the side-effects and the best sequential strategy of implementation of available and emerging drugs.
a Department of Neurology , University Hospital , Bucharest , Romania.
Catalina
C
Coclitu
b Academic Clinical Neurology, Division of Clinical Neuroscience , University of Nottingham , Nottingham , UK.
Cris S
CS
Constantinescu
b Academic Clinical Neurology, Division of Clinical Neuroscience , University of Nottingham , Nottingham , UK.|c Department of Neurology, Neurosurgery and Psychiatry , University of Medicine and Pharmacy Carol Davila, Colentina Hospital , Bucharest , Romania.
Radu
R
Tanasescu
D018450:Disease Progression; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy*
D007166:Immunosuppressive Agents
Multiple sclerosis; immunomodulation; monoclonal antibodies; remyelination; repurposing